Myriad | GenomeWeb


The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

Under the partnership, Myriad will be ION's preferred partner for providing hereditary testing to its member practices. 

The study showed an overall benefit regardless of BRCA mutation or HRD status, but some analysts believe the FDA still might require a CDx for niraparib. 

Although Tesaro used Myriad's BRCA and HRD tests to stratify patients, in the NOVA trial all recurrent ovarian cancer patients benefitted from niraparib. 

The research team's data demonstrated that Sanger confirmation is necessary to provide accurate NGS test results to patients.

The partners will provide testing through a program through which they also plan to establish a database of genetic test results and patient outcomes.

The deal, which included $225 million in upfront payments and up to $185 million in milestones, gives Myriad entry into the neuroscience space.

Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.

After reporting FY2016 revenues below market expectations, Myriad discussed plans to increase sales of Prolaris, Vectra DA, EndoPredict, GeneSight, and myChoice HRD.

The company's revenues were $186.5 million in the fourth quarter and $753.8 million for fiscal year 2016.


Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.